NCT00203073View on ClinicalTrials.gov

A Study to Evaluate the Safety and Effectiveness of Novantrone Therapy Followed by Copaxone for Multiple Sclerosis.

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 30, 2003

Primary Completion Date

January 31, 2005

Study Completion Date

April 30, 2005

Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
DRUG

glatiramer acetate 20 mg

glatiramer acetate 20 mg

DRUG

glatiramer acetate 20 mg, with mitoxantrone

glatiramer acetate 20 mg, with mitoxantrone

All Listed Sponsors
lead

Teva Branded Pharmaceutical Products R&D, Inc.

INDUSTRY

NCT00203073 - A Study to Evaluate the Safety and Effectiveness of Novantrone Therapy Followed by Copaxone for Multiple Sclerosis. | Biotech Hunter | Biotech Hunter